Trial Profile
A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 20 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Planned End Date changed from 1 Jun 2023 to 31 Mar 2024.
- 06 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 31 Mar 2024.